Regulatory pathways for development of antiarrhythmic drugs for management of atrial fibrillation/flutter

Europace

Volumn 13, Issue 8, 2011, Pages 1063-1076

  Savelieva, Irina ^a   Kirchhof, Paulus ^b   Danchin, Nicholas ^c   De Graeff, Pieter A ^d   Camm, A John ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^c HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^d Dutch Medicine Evaluation Board   (Netherlands)

Author keywords

Antiarrhythmic drugs; Atrial fibrillation; Atrial fibrillation burden; Clinical trial; Drug approval; Drug development; EMA; Hospitalization; MACE; Mortality; Outcome; Rate control; Rhythm control

Indexed keywords

AMIODARONE; AMLODIPINE; ANTIARRHYTHMIC AGENT; AZIMILIDE; BMS 914392; BUDIODARONE; CANDESARTAN; DOFETILIDE; DRONEDARONE; FATTY ACID; FLECAINIDE; OLMESARTAN; PROPAFENONE; QUINIDINE; SOTALOL; UNCLASSIFIED DRUG; VALSARTAN; VERAPAMIL;

ABLATION THERAPY; ANTIARRHYTHMIC ACTIVITY; CARDIAC PATIENT; CARDIOVERSION; DEFIBRILLATOR; DISEASE ASSOCIATION; DISEASE COURSE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; ELECTROCARDIOGRAM; EXERCISE TOLERANCE; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART LEFT VENTRICLE FUNCTION; HEART RATE; HEART RHYTHM; HEART VENTRICLE TACHYCARDIA; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; LEFT ATRIAL ABLATION; LENGTH OF STAY; LOW DRUG DOSE; MORBIDITY; MORTALITY; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; PULMONARY VEIN ISOLATION; QUALITY OF LIFE; QUESTIONNAIRE; RECURRENT DISEASE; REVIEW; SINUS RHYTHM; STROKE; SUPRAVENTRICULAR TACHYCARDIA;

ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; ATRIAL FLUTTER; CLINICAL TRIALS AS TOPIC; DRUG APPROVAL; DRUG DESIGN; EUROPE; HUMANS;

EID: 80051752068     PISSN: 10995129     EISSN: 15322092     Source Type: Journal    
DOI: 10.1093/europace/eur181     Document Type: Review

References (52)

1. Heeringa J, van der Kuip DA, Hofman A, Hofman A, Breteler MM, Lip GY et al. Prevalence, incidence and lifetime risk of atrial fibrillation: The Rotterdam study. Eur Heart J 2006;27:949-53.
2. Miyasaka Y, Barnes ME, Gersh BJ, Cha SS, Bailey KR, Abhayaratna WP et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 2006;114:119-25. (Pubitemid 44420743)
3. Naccarelli GV, Varker H, Lin J, Schulman KL. Increasing prevalence of atrial fibrillation and flutter in the United States. Am J Cardiol 2009;104:1534-9.
4. Stefansdottir H, Aspelund T, Gudnason V, Arnar DO. Trend in the incidence and prevalence of atrial fibrillation in Iceland and future projections. Europace 2011;13: 1110-17.
5. Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S et al. Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace 2010;12: 1360-420.
6. Wyse DG,Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002;347:1825-33. (Pubitemid 35417773)
7. Shah AN, Mittal S, Sichrovsky TC, Cotiga D, Arshad A, Maleki K et al. Long-term outcome following successful pulmonary vein isolation: Pattern and prediction of very late recurrence. J Cardiovasc Electrophysiol 2008;19:661-7.
8. Bertaglia E, Tondo C, De Simone A, Zoppo F, Mantica M, Turco P et al. Does catheter ablation cure atrial fibrillation? Single-procedure outcome of drug-refractory atrial fibrillation ablation: A 6-year multicentre experience. Europace 2010;12:181-7.
9. Weerasooriya R, Khairy P, Litalien J, Macle L, Hocini M, Sacher F et al. Catheter ablation for atrial fibrillation are results maintained at 5 years of follow-up? J Am Coll Cardiol 2011;57:160-6.
10. Note for guidance on antiarrhythmics (CPMP/EWP/237/95 final). http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/document/ document-detail.jsp?webContentId=WC500003373&murl=menus/document-library/ document-library.jsp&mid=WC0b01ac058009a3dc (11 May 2011, date last accessed).
11. Savelieva I, Camm J. Anti-arrhythmic drug therapy for atrial fibrillation: Current anti-arrhythmic drugs, investigational agents, and innovative approaches. Europace 2008;10:647-65. (Pubitemid 351775283)
12. Addendum to the Guideline on antiarrhythmics on atrial fibrillation and atrial flutter (EMA/CHMP/EWP/213056/2010). http://www.ema.europa.eu/ema/index. jsp?curl=pages/includes/document/document-detail.jsp?webContentId= WC500096802&murl=menus/document-library/document-library.jsp&mid= WC0b01ac058009a3dc&jsenabled=true (11 May 2011, date last accessed).
13. Kirchhof P, Auricchio A, Bax J, Crijns H, Camm J, Diener HC et al. Outcome parameters for trials in atrial fibrillation: Recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork and the European Heart Rhythm Association. Europace 2007;9:1006-23. (Pubitemid 351773289)
14. Kerr CR, Humphries KH, Talajic M, Klein GJ, Connolly SJ, Green M et al. Progression to chronic atrial fibrillation after the initial diagnosis of paroxysmal atrial fibrillation: Results from the Canadian Registry of Atrial Fibrillation. Am Heart J 2005;149:489-96. (Pubitemid 40585413)
15. de Vos CB, Pisters R, Nieuwlaat R, Prins MH, Tieleman RG, Coelen RJ et al. Progression from paroxysmal to persistent atrial fibrillation clinical correlates and prognosis. J Am Coll Cardiol 2010;55:725-31.
16. Jahangir A, Lee V, Friedman PA, Trusty JM, Hodge DO, Kopecky SL et al. Longterm progression and outcomes with aging in patients with lone atrial fibrillation: A 30-year follow-up study. Circulation 2007;115:3050-6. (Pubitemid 46956493)
17. Fetsch T, Bauer P, Engberding R, Koch HP, Lukl J, Meinertz T et al., Prevention of Atrial Fibrillation after Cardioversion Investigators. Prevention of atrial fibrillation after cardioversion: Results of the PAFAC trial. Eur Heart J 2004;25:1385-94. (Pubitemid 39078247)
18. Oakes RS, Badger TJ, Kholmovski EG, Akoum N, Burgon NS, Fish EN et al. Detection and quantification of left atrial structural remodeling with delayed-enhancement magnetic resonance imaging in patients with atrial fibrillation. Circulation 2009;119:1758-67.
19. Waldo AL, Cooper TB. Spontaneous onset of type I atrial flutter in patients. J Am Coll Cardiol 1996;28:707-12. (Pubitemid 26288654)
20. Waldo AL, Feld GK. Inter-relationships of atrial fibrillation and atrial flutter: Mechanisms and clinical implications. J Am Coll Cardiol 2008;51:779-86. (Pubitemid 351253742)
21. Pérez FJ, Schubert CM, Parvez B, Pathak V, Ellenbogen KA,Wood MA. Long-term outcomes after catheter ablation of cavo-tricuspid isthmus dependent atrial flutter: A meta-analysis. Circ Arrhythm Electrophysiol 2009;2:393-401.
22. Granada J, Uribe W, Chyou PH, Maassen K, Vierkant R, Smith PN et al. Incidence and predictors of atrial flutter in the general population. J Am Coll Cardiol 2000;36: 2242-6.
23. Hohnloser SH, Crijns HJ, van Eickels M, Gaudin C, Page RL, Torp-Pedersen C et al., ATHENA Investigators. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med 2009;360:668-78.
24. Køber L, Torp-Pedersen C, McMurray JJ, Gøtzsche O, Lévy S, Crijns H et al., Dronedarone Study Group. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med 2008;358:2678-87. (Pubitemid 351860860)
25. Hallstrom AP, Greene HL, Wilkoff BL, Zipes DP, Schron E, Ledingham RB, Antiarrhythmics Versus Implantable Defibrillators (AVID) Investigators. Relationship between rehospitalization and future death in patients treated for potentially lethal arrhythmia. J Cardiovasc Electrophysiol 2001;12:990-5. (Pubitemid 32846489)
26. Wyse DG, Slee A, Epstein AE, Gersh BJ, Rocco T Jr, Vidaillet H et al., AFFIRM Investigators. Alternative endpoints for mortality in studies of patients with atrial fibrillation: The AFFIRM study experience. Heart Rhythm 2004;1:531-7. (Pubitemid 39462710)
27. Friberg L, Rosenqvist M. Cardiovascular hospitalization as a surrogate endpoint for mortality in studies of atrial fibrillation: Report from the Stockholm Cohort Study of Atrial Fibrillation. Europace 2011 [Epub ahead of press].
28. Yamashita T, Inoue H, Okumura K, Kodama I, Aizawa Y, Atarashi H et al., on behalf of the J-RHYTHM II Investigators. Randomized trial of angiotensin II-receptor blocker vs. dihydropiridine calcium channel blocker in the treatment of paroxysmal atrial fibrillation with hypertension (J-RHYTHM II Study). Europace 2011;13:473-9.
29. Goette A, Breithardt G, Fetsch T, Hanrath P, Klein HU, Lehmacher W et al. Angiotensin II antagonist in paroxysmal atrial fibrillation (ANTIPAF) trial: Rationale and study design. Clin Drug Investig 2007;27:697-705. (Pubitemid 47481702)
30. Patten M, Maas R, Karim A, Müller HW, Simonovsky R, Meinertz T. Event-recorder monitoring in the diagnosis of atrial fibrillation in symptomatic patients: Subanalysis of the SOPAT trial. J Cardiovasc Electrophysiol 2006;17: 1216-20. (Pubitemid 44583865)
31. Page RL, Tilsch TW, Connolly SJ, Schnell DJ, Marcello SR, Wilkinson WE et al., Azimilide Supraventricular Arrhythmia Program (ASAP) Investigators. Asymptomatic or 'silent' atrial fibrillation: Frequency in untreated patients and patients receiving azimilide. Circulation 2003;107:1141-5. (Pubitemid 36300748)
32. Blaauw Y, Schotten U, van Hunnik A, Neuberger HR, Allessie MA. Cardioversion of persistent atrial fibrillation by a combination of atrial specific and non-specific class III drugs in the goat. Cardiovasc Res 2007;75:89-98. (Pubitemid 46873519)
33. Brignole M, Vardas P, Hoffman E, Huikuri H, Moya A, Ricci R et al., EHRA Scientific Documents Committee; Document Reviewers. Indications for the use of diagnostic implantable and external ECG loop recorders. Europace 2009;11: 671-87.
34. Van Gelder IC, Wyse DG, Chandler ML, Cooper HA, Olshansky B, Hagens VE et al., RACE and AFFIRM Investigators. Does intensity of rate-control influence outcome in atrial fibrillation? An analysis of pooled data from the RACE and AFFIRM studies. Europace 2006;8:935-42. (Pubitemid 44614202)
35. Van Gelder IC, Groenveld HF, Crijns HJ, Tuininga YS, Tijssen JG, Alings AM et al., RACE II Investigators. Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med 2010;362:1363-73.
36. Wilkoff BL, Ousdigian KT, Johnson WB, Koehler JL. New continuous atrial tachyarrhythmia rate control diagnostic reveals significantly more patients have poor rate control than discovered via intermittent evaluations. Heart Rhythm 2006;3:S127-8. (Abstract).
37. Sarkar S, Koehler J, Crossley GH, Tang WHW, Abraham WT, Whellan DJ. Burden of atrial fibrillation and poor rate control detected by continuous monitoring via implanted devices identifies when a patient is at risk for heart failure hospitalization. J Amer Coll Cardiol 2011 (Abstract 1090-390).
38. Savelieva I, Camm AJ. Clinical relevance of silent atrial fibrillation: Prevalence, prognosis, quality of life, and management. J Interv Card Electrophysiol 2000;4: 369-82.
39. Hagens VE, Van Veldhuisen DJ, Kamp O, Rienstra M, Bosker HA, Veeger NJ et al., RAte Control versus Electrical Cardioversion for Persistent Atrial Fibrillation Study Group. Effect of rate and rhythm control on left ventricular function and cardiac dimensions in patients with persistent atrial fibrillation: Results from the RAte Control versus Electrical Cardioversion for Persistent Atrial Fibrillation (RACE) study. Heart Rhythm 2005;2:19-24. (Pubitemid 40104304)
40. Hindricks G, Piorkowski C, Tanner H, Kobza R, Gerds-Li JH, Carbucicchio C et al. Perception of atrial fibrillation before and after radiofrequency catheter ablation: Relevance of asymptomatic arrhythmia recurrence. Circulation 2005; 112:307-13. (Pubitemid 41022070)
41. Vasamreddy CR, Dalal D, Dong J, Cheng A, Spragg D, Lamiy SZ et al. Symptomatic and asymptomatic atrial fibrillation in patients undergoing radiofrequency catheter ablation. J Cardiovasc Electrophysiol 2006;17:4-9.
42. Pontoppidan J, Nielsen JC, Poulsen SH, Hansen PS. Symptomatic and asymptomatic atrial fibrillation after pulmonary vein ablation and the impact on quality of life. Pacing Clin Electrophysiol 2009;32:717-26.
43. Savelieva I, Paquette M, Dorian P, Lüderitz B, Camm AJ. Quality of life in patients with silent atrial fibrillation. Heart 2001;85:216-7. (Pubitemid 32973598)
44. Spertus J, Dorian P, Bubien R, Lewis S, Godejohn D, Reynolds MR et al. Development and validation of the Atrial Fibrillation Effect on QualiTy-of-Life (AFEQT) Questionnaire in patients with atrial fibrillation. Circ Arrhythm Electrophysiol 2011;4:15-25.
45. Lane DA, Langman CM, Lip GY, Nouwen A. Illness perceptions, affective response, and health-related quality of life in patients with atrial fibrillation. J Psychosom Res 2009;66:203-10.
46. Arribas F, Ormaetxe JM, Peinado R, Perulero N, Ramírez P, Badia X. Validation of the AF-QoL, a disease-specific quality of life questionnaire for patients with atrial fibrillation. Europace 2010;12:364-70.
47. Braganca EO, Filho BL, Maria VH, Levy D, de Paola AA. Validating a new quality of life questionnaire for atrial fibrillation patients. Int J Cardiol 2010;143: 391-8.
48. Guédon-Moreau L, Capucci A, Denjoy I, Morgan CC, Périer A, Leplège A et al. Impact of the control of symptomatic paroxysmal atrial fibrillation on health-related quality of life. Europace 2010;12:634-42.
49. Kosior DA, Stawicki S,Wozakowska-Kaplon B, Szulc M, Opolski G, Rabczenko D. Impact of sinus rhythm restoration and maintenance on left ventricular function and exercise tolerance in patients with persistent atrial fibrillation. Kardiol Pol 2005;63:36-47.
50. Shelton RJ, Clark AL, Goode K, Rigby AS, Houghton T, Kaye GC et al. A randomised, controlled study of rate versus rhythm control in patients with chronic atrial fibrillation and heart failure: (CAFE-II Study). Heart 2009;95:924-30.
51. Wilton SB, Fundytus A, Ghali WA, Veenhuyzen GD, Quinn FR, Mitchell LB et al. Meta-analysis of the effectiveness and safety of catheter ablation of atrial fibrillation in patients with versus without left ventricular systolic dysfunction. Am J Cardiol 2010;106:1284-91.
52. Atwood JE, Myers JN, Tang XC, Reda DJ, Singh SN, Singh BN. Exercise capacity in atrial fibrillation: A substudy of the Sotalol-Amiodarone Atrial Fibrillation Efficacy Trial (SAFE-T). Am Heart J 2007;153:566-72. (Pubitemid 46440682)